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Abstract
Background: Microsatellite instability (MSI) at tri- or tetranucleotide repeat markers (elevated
microsatellite alterations at selected tetranucleotide repeat, EMAST) has been recently described.
But, the underlying genetic mechanism of EMAST is unclear. This study was to investigate the
prevalence of EMAST, in type I endometrial carcinoma, and to determine the correlation between
the MSI status and mismatch repair genes (MMR) or p53.
Methods: We examined the 3 mono-, 3 di-, and 6 tetranucleotide repeat markers by PCR in 39
cases of type I endometrial carcinoma and performed the immunohistochemistry of hMSH2,
hMLH1, and p53 protein.
Results: More than two MSI at mono- and dinucleotide repeat markers was noted in 8 cases (MSI-
H, 20.5%). MSI, at a tetranucleotide repeat, was detected in 15 cases (EMAST, 38.5%). In remaining
16 cases, any MSI was not observed. (MSS, 42.1%), MSI status was not associated with FIGO stage,
grade or depth of invasion. The absence of expression of either one of both hMSH2 or hMLH1 was
noted in seven (87.5%) of eight MSI-H tumors, one (6.3%) of 16 MSS tumors, and five (33.3%) of
15 EMAST tumors. (p = 0.010) The expression of p53 protein was found in one (12.5%) of eight
MSI-H tumors, five (31.3%) of 16 MSS tumors, and seven of 15 EMAST tumors. (p = 0.247)
Conclusion: Our results showed that about 38.5% of type I endometrial carcinomas exhibited
EMAST, and that EMAST was rarely associated with alteration of hMSH2 or hMLH1.
Background
Inherited defects in DNA mismatch repair (MMR) genes,
usually hMLH1 or hMSH2, lead to microsatellite instabil-
ity (MSI) and subsequent malignancy in hereditary non-
polyposis colon cancer (HNPCC) [1]. While typical of
HNPCC cancers, MSI also occurs in a minority of sporadic
cancer [2]. Recently, a distinct type of MSI has been
described where microsatellite alterations are present at
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selected tetranucleotide repeat regions; this is referred to
as 'elevated microsatellite alterations at selected tetranu-
cleotide repeats' (EMAST) [3-5]. Although the genetic
basis for MSI associated with defective MMR is being
increasingly clarified, the mechanism underlying micros-
atellite alterations for EMAST tumors remains to be
unclear [3]. Recent work has suggested that EMAST may
be associated with alterations in the tumor suppressor
gene p53 [4,6].
The incidence of MSI in endometrial carcinoma has
recently been described in several articles. It has been
shown to be present in 25% to 30% of type I endometrial
carcinoma, which is related with estrogenic stimulation,
and has been rarely demonstrated in type II endometrial
carcinoma, which is unrelated with estrogen [10-12].
However, EMAST in endometrial carcinoma has not yet
been studied. The aim of the current study was to evaluate
the prevalence and clinicopathologic significance of MSI
including EMAST in sporadic type I endometrial carci-
noma. We also examined the association between
hMLH1, hMSH2 or p53 and EMAST using immunohisto-
chemical staining techniques.
Methods
Sample collection
Formalin-fixed, paraffin-embedded tissue samples from
sporadic type I endometrial carcinomas were selected
from 39 patients who had undergone hysterectomy at
Chonnam National University Hospital during the period
from 1998 to 2002. None of these patients met the criteria
for a diagnosis of HNPCC. Normal lymph node tissue
from the same patient was used for control DNA samples.
Hematoxylin and eosin (H&E) -stained slides from each
case was reviewed previously for determination of depth
of invasion and grade. Histological grade and stage were
assigned according to the International-Federation of
Obstetrics and Gynecology (FIGO) criteria. The depth of
myometrial invasion was divided into no evidence of
myometrial invasion, ≤ 50% and > 50%.
Microsatellite instability assay
1) DNA extraction
Paraffin embedded normal and tumor tissues were cut
into 10 § sections. The tumor cells were microdissected
under the microscope on the H-E stained slide. One tissue
section from each case was transferred with an disposable
razor blade to 1 ml of xylene in a 1.5 ml microcentrifuge
tube. An equal volume of 100% ethanol was added and
the samples were pelleted (10 minutes in microcentri-
fuge), dried under a vacuum, and digested overnight with
TEN buffer (0.1 M NaCl, 10 mM Tris·Cl pH 8.0, 1 mM
EDTA pH 8.0) 375 μl, 10% SDS 25 μl, and 20 μg/μl pro-
teinase K 15 μl at 56°. The DNA was isolated by phenol-
chloroform extraction and ethanol precipitation.
2) Polymerase Chain Reaction
Each matched pair of normal and tumor DNA was subject
to PCR analysis with 12 microsatellite markers. The tetra-
nucelotide repeat markers were MYCL1, D19S394,
D9S242, UT5320, D8S321, and L17686. Dinucleotide
repeat markers were D2S123, D17S250, and D8S554.
Mononucleotide repeat markers were BAT25, BAT 26, and
BAT40.
Primer sequences for PCR amplification of microsatellite
loci were designed and are shown in Table 1. PCR was per-
formed in a total volume of 20 μl with 10–20 ng DNA,
0.175 uM each primer, 2 mM dNTP, 15 mM MgCl2 and
0.5 units of Taq polymerase (Supertaq, Republic of
Korea). PCR conditions consisted of 28 to 35 cycles at 92°
for 1 min, 53° ~63° for 1 min and 72° for 1 min. The
annealing temperature was determined empirically for
each primer pair. For microsatellite analysis, one primer
was end-labeled with T4 polynucleotide kinase (Takara,
Japan) and 32P-γ [dATP]. PCR products were separated by
electrophoresis in denaturing 7 M urea/6% polyacryla-
mide gels followed by autoradiography.
3) Criteria for EMAST, MSI, and MSS
EMAST was determined when the new peak, in the tumor
samples, appeared in more than one of the tetranucle-
otide repeat markers, but was not present in the mono or
dinucleotide repeat markers. A high frequency of MSI
(MSI-H) was present when new peak were observed at two
or more (≥ 30–40%) in mono or dinucleotide repeat
markers. A low frequency of MSI (MSI-L) was present
when the new peak was at one mono or dinucleotide
repeat marker. Microsatellite stable (MSS) was present
when there was no new peak observed in any of the repeat
markers studied.
Immunohistochemical staining
The immunohistochemical staining in formalin-fixed,
paraffin-embedded sections was performed with the
labeled avidin-biotin complex peroxidase-AEC (3-amino-
9-ethylcarbazol) system. Tissue sections on glass slides
were de-paraffinized with xylene, hydrated in serially
diluted alcohol, and then immersed in 3% H2O2 in order
to quench endogenous peroxidase activity. Antigen
retrieval was performed using citrate buffer (Antigen
Retrieval Citra; Biogenex, San Ramon, CA, USA) with a
pressure cooker. The sections were then incubated with
anti-hMLH1 (mouse monoclonal; 1:100 dilution; Zymed,
San Francisco, USA), anti-hMSH2 (mouse monoclonal;
1:100 dilution; Zymed, San Francisco, USA), and anti-p53
(mouse monoclonal; 1:100 dilution; DAKO, Carpinteria,
USA). The tissue sections were incubated with horseradish
peroxidase (HRP) -conjugated streptavidin and chro-
mogen were developed, and counter-stained with hema-
toxylin. The staining of tumor nuclei for hMLH1  andJournal of Experimental & Clinical Cancer Research 2008, 27:88 http://www.jeccr.com/content/27/1/88
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hMSH2 was evaluated and noted as absent or present. For
hMLH1 and hMSH2, loss of nuclear protein expression in
tumor cells was considered as a defect in the hMLH1 or
hMSH2 gene. The immunostaining for p53 was evaluated
within tumor nuclei and divided to absent or present.
Statistical analysis
We performed statistical analysis using the Fisher's exact
test between clinicopathologic status or extent of positive
immunoreactivity and the MSS, MSI and EMAST groups.
All p values represent two-sided statistical tests with statis-
tical significance at p < 0.05.
Results and discussion
Results
CLINICOPATHOLOGIC DATA
The patient age ranged from 30 to 68 (mean 53.4) years.
Grade 1 was seen in 20 tumors; grade 2, in 11 tumors; and
grade 3, in eight tumors. Most of the patients were FIGO
stage I or II (33 of 39; 84.6%), and only six tumors were
identified as stage III. In 15 (38.5%) tumors, the tumor
was confined to endometrium. A more than 50% myome-
trial invasion was seen in six tumors (15.4%), and less
than 50% in 18 tumors (46.1%). (Table 2)
Molecular data
Successful PCR amplification of six mono- or dinucle-
otide repeat markers and six tetranucleotide markers was
obtained for 39 tumors and each normal lymph node
samples. The data is shown in Table 2. Microsatellite
instability at mono- or dinucleotide repeat markers was
noted in eight of 39 tumors (20.5%). All eight tumors dis-
played MSI at two or more loci for mono and dinucleotide
repeat markers. Therefore, these eight tumors were catego-
rized as the MSI-H group. There were no tumors classified
as MSI-L. The MSI rates at mono or dinucleotide repeat
markers were as follows: 15.4% (6/39) in BAT25, 12.8%
(5/39) in BAT26, 17.9% (7/39) in BAT40, 5.1% (2/39) in
D17S250, 12.8% (5/39) in D8S554, and 10.3% (4/39) in
D2S123. (Figure 1) Microsatellite instability at tetranucle-
otide repeat markers was observed in 15 of 39 tumors
(38.5%). All 15 tumors did not exhibit any MSI at the
mono- or dinucleotide repeat markers, and were catego-
rized as EMAST. Among 15 EMAST tumors, 11 tumors dis-
played MSI at one locus for tetranucleotide repeat
markers, three displayed at two loci, and one displayed at
three loci. The highest MSI rates, for tetranucleotide repeat
markers, were seen in L17686 (7/39, 17.9%), followed by
D9S242 (4/39, 10.3%), UT5320 (4/39, 10.3%), MYCL1
Table 1: Microsatellite primer for MSI assay
Primer Primer sequence AT(°) PCRcycle Repeat type
BAT25 Forward : 5'-TCGCCTCCA AGAATGTAA GT-3' 55 28 Mono
Reverse: 5'-TCTGGATTTTAACTATGGCTC-3'
BAT26 Forward : 5'-TGACTACTTTTGACTTCAGCC-3' 55 30
Reverse: 5'-GTTTCTAACCATTCAACATTTTTATCCC-3'
BAT40 Forward : 5'-GTAGAGCAAGACCACCTTG-3' 55 30
Reverse: 5'-GTTTCTACAACCCTGCTTTTGTTCCT-3'
D2S123 Forward : 5'-AAACAGGATGCCTGCCTTTA-3' 55 35 Di
Reverse: 5'-GGACTTTCCACCTATGGGAC-3'
D17S250 Forward : 5'-GGAAGAATCAAATAGACAAT-3' 55 35
Reverse: 5'-GCTGGCCATATATATATTTAAACC-3'
D8S554 Forward : 5'-TTTCCAGACAGGGCCTA-3' 58 35
Reverse: 5'-AATGCACAGGACATAATTT-3'
MYCL1 Forward : 5'-TGGCGAGACTCCATCAAAG-3' 58 35 Tetra
Reverse: 5'-CCTTTTAAGCTGCAACAATTTTC-3'
D19S394 Forward : 5'-AGACTACAGYGAGCTGTGG-3' 58 35
Reverse: 5'-GTGTTCCTAACTACCAGGC-3'
D9S242 Forward : 5'-GTGAGAGTTCCTTCTGGC-3' 56 35
Reverse: 5'-ACTCCAGTACAAGACTCTG-3'
UT5320 Forward : 5'-ACCGACAGACTCTTGCCTC-3' 58 35
Reverse: 5'-TTGAGATGACCCTGAGACTG-3'
D8S321 Forward : 5'-GATGAAAGAATGATAGATTACAG-3' 58 35
Reverse: 5'-ATTCTTCTCATGCCATATCTGC-3'
L17686 Forward : 5'-GCACCAATGCTCCAGAAATG-3' 63 35
Reverse: 5'-TCATGGTGCCATGATAGGAG-3'
AT : Annealing temperature.
Mono : Mononucleotide repeat.
Di : Dinucleotide repeat.
Tetra : Tetranucleotide repeatJ
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Table 2: Clinicopathologic features, MSI status, and the expression of hMSH2, hMLH1, and p53 protein in type I endometrial carcinomas
No. Immunohistochemistry Tetranucleotide repeat Mononucleotide repeat Dinucleotide repeat Subtype of
Age Stage Grade Depth hMSH2 hMLH1 P53 MYCL1 UT5320 D19S394 D9S242 L17686 D8S321 BAT25 BAT26 BAT40 D17S250 D8S554 D2S123 MSI
1 50 III 2 >50% + + + H MSI H H H H H H H H H H EMAST
2 67 I 1 <50% + + - H H H H H H MSI MSI H H MSI H MSI-H
3 56 III 1 <50% + + + H H H H H H H H H H H H MSS
44 3 I 3 E m + + + H H H H H H H H H H H H M S S
53 9 I I 1 < 5 0 % + + - H H H M S I H H H H H H H H E M A S T
65 0 I 1 < 5 0 % + + - H H H H H H H H H H H H M S S
7 54 I 2 <50% - + - H H H H H H MSI H MSI H MSI MSI MSI-H
8 40 I 2 <50% - - - H H H H H H MSI H MSI H H H MSI-H
95 1 I 1 E m + + - H H H H H H H H H H H H M S S
10 55 I 1 <50% - + - MSI H H H MSI H H H H H H H EMAST
11 60 I 1 <50% + + - H H H H H H H H H H H H MSS
12 68 III 2 >50% - - - H H H H H H H MSI MSI H MSI H MSI-H
13 55 I 1 Em + + + H MSI H H H H H H H H H H EMAST
14 66 I 2 <50% - + - H H H H H H H H H H H H MSS
15 60 I 2 Em - + - H H H MSI H H H H H H H H EMAST
16 42 I 1 Em + + - H H H H H H H H H H H H MSS
17 53 I 2 Em + + - H H H H H H H H H H H H MSS
18 63 I 3 >50% - - + H H H H H H MSI H MSI H MSI MSI MSI-H
19 58 I 1 Em + + - H H H H H H H H H H H H MSS
20 36 I 1 Em + + - H H H H H H H H H H H H MSS
21 40 III 1 <50% + + - H H H H MSI H H H H H H H EMAST
22 68 I 1 <50% + - - H H H H H H MSI MSI MSI H H H MSI-H
23 41 I 2 Em + + + H H H H MSI H H H H H H H EMAST
24 50 I 2 <50% + + - H H H H H H H H H H H H MSS
25 54 I 1 Em + + - H MSI H H MSI H H H H H H H EMAST
26 51 I 3 <50% + - - MSI MSI MSI H H H H H H H H H EMAST
27 63 I 3 Em + + + H H H H H H H H H H H H MSS
28 46 I 3 Em + + + H H H H H H H H H H H H MSS
29 64 III 3 >50% + + + H H H H MSI H H H H H H H EMAST
30 44 II 3 Em + + + H H H MSI H H H H H H H H EMAST
31 55 III 3 >50% - + + H H H H MSI H H H H H H H EMAST
32 44 I 1 <50% - - - H H H H H H MSI MSI MSI MSI H MSI MSI-H
33 43 I 1 <50% + + - H H H MSI H H H H H H H H EMAST
34 55 I 1 <50% + + + H H H H H H H H H H H H MSS
35 51 I 1 >50% + + - H H H H H H H H H H H H MSS
36 33 I 2 Em + + - H H H H H H H H H H H H MSS
37 49 I 1 Em + - - MSI H H MSI H H H H H H H H EMAST
38 52 I 1 <50% + + + H H H H H MSI H H H H H H EMAST
39 30 I 2 <50% + - - H H H H H H H MSI MSI MSI MSI MSI MSI-H
Em : Endometrium H: Heterozygosity.
MSS : Microsatellite stable.
MSI : Microsatellite instability.
MSI-H : Microsatellite instability – high frequency.
EMAST : Elevated microsatellite alterations at selected tetranucleotide repeat.Journal of Experimental & Clinical Cancer Research 2008, 27:88 http://www.jeccr.com/content/27/1/88
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(3/39, 7.7%), D19S394 (1/39, 2.6%), and D8S321 (1/39,
2.6%). (Figure 2) MSI was not observed in 16 of 39
tumors (41.0%) for all markers studied. Therefore, these
16 tumors were categorized as MSS. There was no signifi-
cant differences between MSI-H, EMAST and MSS group
in respect to stage (p = 0.28), grade (p = 0.66) and depth
of invasion (p = 0.06). (Table 3)
Immunohistochemical staining data
1) hMSH2 and hMLH1
Loss of nuclear hMSH2 protein expression was seen in
23.0% (9 of 39), and loss of hMLH1 in 20.5% of tumors
(8 of 39). In 13 of total 39 tumors (33.3%), the protein
expression loss was found at least one of either hMSH2 or
hMLH1. (Figure 3) No correlation between the loss of
hMSH2  or  hMLH1  and clinicopathologic data was
observed. Loss of hMSH2 or hMLH1 was mainly seen in
MSI-H group (7 of 8), and was rarely seen in MSS group
(1 of16). The MSI-H group was significantly correlated
with loss of at least one of both proteins. (p < 0.01) In
33.3% (5 of 15) of EMAST group, the loss of hMSH2 or
hMLH1 was observed. (Table 4) Of 11 tumors that dis-
played MSI at one locus for tetranucleotide markers, nine
tumors showed positive immunoreactivity for both
hMSH2 and hMLH1. Of four tumors that displayed MSI at
two or three loci for tetranucleotide repeat markers, three
tumors showed the expression loss of at least one of either
hMSH2 or hMLH1.
2) p53
The p53 immunohistochemical expression was noted in
31.3% (5 of 16) of MSS, 12.5% (1 of 8) of MSI-H, and
46.7% (7/15) of EMAST. Although p53 expression was
more common in the EMAST group than the other
groups, the difference was not statistically significant. (p =
0.25) (Table IV). The p53 expression was noted in seven
of 11 tumors that displayed MSI at one locus for tetranu-
cleotide markers (63.6%). None of four tumors displayed
MSI at two or three loci for tetranucleotide markers
showed the p53 expression. For the clinicopathologic
data, p53 expression was not correlated with stage and
depth of invasion. But, observation of p53 expression was
noted in 87.5% (7/8) of grade 3, 18.2% (2/11) of grade 2,
and 20.0% (4/20) of grade 1 tumors. Thus, p53 expres-
sion was highly associated with FIGO grade 3 tumors. (p
< 0.01)
Discussion
In our study, the incidence of EMAST in type I endomte-
rial carcinoma was 38.5%. To date, those tumors showing
the highest levels of EMAST are associated with known
environmental carcinogens, for example, cigarette smok-
ing or sunlight exposure, suggesting a causal relationship
[13]. For example, EMAST is common in head and neck
(56%), lung (51%) and bladder cancer (21–40%), but
infrequently found in renal (12%) and prostate cancer
(6%) [5,14]. Danaee et al. found 75.4% and 43.3% of MSI
at tetranucleotide repeat markers in non-melanomatous
skin cancer and bladder tumors, respectively [14].
Wooster  et al. reported that human cancers including
breast (11%), brain (2%), ovarian (10%) cancers and soft
tissue sarcoma (11%) exhibited EMAST [15]. The EMAST
rate in type I endometrial cancer was relatively higher than
that of kidney, prostate, brain and ovary. The estrogen
which is widely known as a causal factor in type I endome-
trial carcinoma can be possible as a novel factor associated
with EMAST. However, the tetranucleotide repeat makers
are different between our study and others. In order to
clarify whether the estrogen is associated with EMAST or
not, a standard gene panel for EMAST study, like Bethesda
panel used in mono- & dinucleotide repeat markers [3],
should be requested.
Seven of eight MSI-H tumors (87.5%) of our study
showed a loss of at least one of both hMLH1 and hMSH2.
However, for the EMAST group, it was observed in five of
15 tumors (33.3%). Malfunction of the MMR genes
including hMLH1 and hMSH2 can result from a somatic
mutation, deletion, and hypermethylation of the coding
MSI at mono- and dinucleotide repeat markers in type I  endometrial carcinioma Figure 1
MSI at mono- and dinucleotide repeat markers in 
type I endometrial carcinioma. Alterations in the elec-
trophoretic mobility of PCR products from tumor compared 
with normal tissue DNA are seen (arrowheads). (N: normal, 
T: tumor).
MSI at tetranucleotide repeat markers (EMAST) in type I  endometrial carcinioma Figure 2
MSI at tetranucleotide repeat markers (EMAST) in 
type I endometrial carcinioma. Alterations in the elec-
trophoretic mobility of PCR products from tumor compared 
with normal tissue DNA are seen (arrowheads). (N: normal, 
T: tumor).Journal of Experimental & Clinical Cancer Research 2008, 27:88 http://www.jeccr.com/content/27/1/88
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region. In sporadic endometrial carcinoma cell lines,
somatic mutations are infrequent, and hypermethylation
of the hMLH1 promoter region appears to be the main
cause of gene silencing [21,22]. Thus, our results said that
a defect of hMLH1 or hMSH2 was less frequently detected
in EMAST group than MSI-H group.
The majority of sporadic endometrial carcinomas (at least
approximately 70%–80%), are designated as type I
endometrial carcinomas and are estrogen related. Histo-
logically, most type I endometrial carcinomas show an
endometrioid differentiation and are of low grade. About
10–20% of endometrial carcinomas, designated as type II
endometrial carcinomas, are estrogen-unrelated; these
tumors usually present in older patients and are typically
high-grade carcinomas, with non-endometrioid differen-
tiation [8]. Molecular data from multiple studies support
the hypothesis of different genetic pathways for the devel-
opment of type I and type II endometrial carcinoma. The
most frequent alteration in type 1 endometrial carcinoma
is the PTEN inactivation by mutation, followed by MSI
and mutations of K-ras and  -catenin. In type II endome-
trial carcinoma, alterations of p53 and loss of heterozy-
gosity (LOH), at several chromosomal loci, are thought to
drive the process of neoplastic transformation [8,9]. In
this study, the incidence of MSI, in type I endometrial car-
cinoma, is similar to that previously reported [10,12]. Our
study for type I endometrial carcinomas showed no signif-
icant differences between three groups with regard to
stage, FIGO grade, and the extent of myometrial invasion.
Peiro et al. reported that tumors in an advanced FIGO
stage (III to IV) were more frequently MSI positive than
those in a low stage (I to II) [20]. This difference can be
interpretated as two problems : 1) Peiro's study included
type II endometrial carcinomas as well as type I endome-
trial carcinomas. 2) The samples included in our study are
not evenly distributed in aspect of FIGO stage. Most of the
samples were FIGO stage I or II (33 of 39; 84.6%). The
unbalanced stage of our study' cases seems to be a factor
affecting the result.
Alteration of the p53 gene is a common event in many
cancers, and is primarily associated with protein overex-
pression. Given its role in maintaining genomic stability,
it is possible that altered p53 might play a mechanistic
role in the genesis of EMAST [14]. In fact, a recent report
by Ahrendt et al. found that most tumors with EMAST also
Table 3: MSI status in relation to clinicopathologic features.
No. MSS MSI-H EMAST p-value
Stage I or II 33 15(93.8%) 7(78.5%) 11(73.3%) 0.28
III 6 1(6.2%) 1(12.5%) 4(26.7%)
Grade 1 20 9(56.3%) 3(37.5%) 8(53.3%) 0.66
2 11 4(25.0%) 4(50.0%) 3(20.0%)
3 8 3(18.7%) 1(12.5%) 4(26.7%)
Depth Endometrium 15 9(56.3%) 0(0.0%) 6(40.0%) 0.06
<50% of myometrium 18 6(37.5%) 6(75.0%) 6(40.0%)
>50% of myometrium 6 1(6.2%) 2(25.0%) 3(20.0%)
Total 39 16(41.0%) 8(20.5%) 15(38.5%)
MSS : Microsatellite stable.
MSI : Microsatellite instability – high frequency.
EMAST : Elevated microsatellite alterations at selected tetranucleotide repeat.
Examples of type I endometrial carcinoma with (A) loss of  hMSH2 protein expression, (B) preservation of hMSH2 pro- tein expression, (C) loss of hMLH1 protein expression, and  (D) preservation of hMLH1 protein expression Figure 3
Examples of type I endometrial carcinoma with (A) 
loss of hMSH2 protein expression, (B) preservation of 
hMSH2 protein expression, (C) loss of hMLH1 protein 
expression, and (D) preservation of hMLH1 protein 
expression. Positive expression for hMSH2 or hMSH1 is 
noted in non-tumor cells. (A-D, X200).Journal of Experimental & Clinical Cancer Research 2008, 27:88 http://www.jeccr.com/content/27/1/88
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had p53 gene mutations [4]. In this study, although the
p53 gene was expressed more in EMAST (+) tumors than
EMAST (-) tumors, this difference was not statistically sig-
nificant. The p53 mutation was known as a genetic altera-
tion in type II endometrial carcinomas [24]. However,
p53 mutation was also found in a subset of approximately
10–20% of type I endometrial carcinomas, which were
mostly grade 3 tumors [25]. Catasus et al. found that most
grade 3 tumors in type I endometrial carcinomas showed
the immunohistochemical expression for p53 [10], this
finding is presented in our result. The p53 protein was
highly expressed in grade 3 tumors (p < 0.001).
Among tetranucleotide repeat markers that were exam-
ined in our study, MSI was highly detected in L17686 gene
(7/39). The gene is located in long arm of chromosome 7,
and was also highly detected marker in lung cancer and
head & neck cancer [17]. UT5320 and MYCL1 that showed
the higher detection rate in bladder cancer were observed
in 10.3% (4/39) and 7.7% (3/39) in type I endometrial
carcinomas of our study, respectively [18,19]. The detec-
tion rate at each tetranucleotide repeat maker seems to be
different according to organ or tumor types. In order to
solve this question, EMAST study within more various
organ and tumor types should be preceded.
To date, seven human MMR genes whose products func-
tion in MMR have been identified. These include
homologs of the Escherichia coli mutS – hMSH2, hMSH3,
hMSH6 -, and mutL homologs – hMLH1, hPMS2, hMLH3
and hPMS1 [26,27]. DNA strand slippage at tri- or tetranu-
cleotide repeats during replication will result in formation
of loops containing more than three extra nucleotides. A
complex between the heterodimer MutLα ( hMLH1/
hPMS2) and the heterodimer MutSβ (hMSH2/hMSH3) is
responsible for repairing these loops [28]. Recently, yeast
MLH3 was found to form a complex with y MLH1 and to
participate in repairing some groups of loops in collabo-
ration with MutSβ. This suggests that hMLH3, a homolog
of yeast MLH3, might have a similar function. Therefore,
the loss of the hMSH3 and/or hMLH3 function may result
in loss of loop repair, and eventually may be responsible
for EMAST. This should inspire further investigations to
prove a correlation between hMSH3 and/or hMLH3 and
EMAST
In this study, 11 tumors of 15 EMAST (73.3%) showed
MSI at one locus for tetranucleotide repeats, and four
tumors (26.7%) showed MSI at two or more loci. Of 11
tumors, a defect of hMLH1  or  hMSH2  expression was
found in 18.2% (2 of 11) and p53 overexpression was
observed in 63.6% (7 of 11). In 4 tumors at two or more
loci, 3 tumors of 4 showed the expression loss of hMLH1
or hMSH2 and none showed the p53 expression. It is pos-
sible to be a different genetic alteration between two
groups. However, after the molecular events associated
with EMAST become clear, the research about the genetic
difference appears to be a subject.
In conclusion, the incidence of EMAST in endometrioid
carcinoma was 38.5%, and an alteration of hMSH2  or
hMLH1 was not frequent in EMAST.
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